OsPhos (clodronate disodium) and Tildren (tiludronate disodium) are bisphosphonate drugs FDA-approved for the control of clinical signs associated with navicular syndrome (podotrochlear apparatus pain) in horses. Bisphosphonates are a class of drugs that inhibit bone resorption by targeting osteoclasts. They represent a relatively recent addition to the equine therapeutic arsenal for managing navicular disease and other conditions involving pathologic bone remodeling.
Overview
Bisphosphonates work by binding to hydroxyapatite crystals in bone and being taken up by osteoclasts during bone resorption. Inside the osteoclast, bisphosphonates disrupt cellular metabolism and induce apoptosis, thereby reducing excessive bone resorption. In navicular syndrome, abnormal bone remodeling within the navicular bone contributes to pain and lameness. By slowing this process, bisphosphonates can reduce pain and improve soundness.
OsPhos (clodronate) is a non-nitrogen-containing bisphosphonate given as an intramuscular injection. Tildren (tiludronate) is also a non-nitrogen-containing bisphosphonate but is administered via slow intravenous infusion. Both are single-treatment protocols that may be repeated based on clinical response.
Uses
- Navicular syndrome / Podotrochlear pain — FDA-approved indication for both products
- Navicular bone sclerosis and remodeling — associated with clinical lameness
- Other bone remodeling conditions — off-label use in conditions such as bone spavin, stress fractures, and pedal osteitis has been explored, though evidence is limited
Dosage
Administered by a veterinarian only.
| Product | Active Ingredient | Dose | Route | Protocol |
|---|---|---|---|---|
| OsPhos | Clodronate disodium | 1.14 mg/kg (approximately 3 mL per 100 kg) | Intramuscular (divided into 3 injection sites in the neck) | Single treatment; may repeat no sooner than 3-6 months |
| Tildren | Tiludronate disodium | 1 mg/kg diluted in 1 L saline | Slow IV infusion over 60-90 minutes | Single treatment; may repeat no sooner than 3-6 months |
OsPhos is given IM, divided across 3 neck injection sites to reduce local irritation. Tildren requires IV infusion with cardiac monitoring. Clinical improvement may take 2-8 weeks after administration, as the bone remodeling effects are gradual.
Side Effects
| Common | Serious (Contact Your Vet) |
|---|---|
| Signs of discomfort during/after injection (pawing, lip curling, colic-like behavior) | Renal toxicity (rare, primarily with IV bisphosphonates in dehydrated horses) |
| Transient restlessness or agitation | Prolonged GI distress |
| Injection site soreness (OsPhos IM) | Esophageal or gastric irritation (reported with oral bisphosphonates in other species) |
| Mild, transient colic-like signs | Hypocalcemia (rare) |
| Decreased appetite (24-48 hours) |
Post-injection behavioral signs (agitation, pawing, flank-watching) are common with OsPhos and typically resolve within 15-60 minutes. Pretreatment with flunixin meglumine may reduce these signs. Tildren IV infusion may cause signs of discomfort during administration; slowing the infusion rate often helps.
Drug Interactions
- NSAIDs (flunixin, phenylbutazone): Often administered concurrently to manage post-injection discomfort. No adverse pharmacologic interaction, but the nephrotoxic potential of NSAIDs combined with bisphosphonates warrants attention to hydration status.
- Aminoglycoside antibiotics (gentamicin): Theoretical additive nephrotoxic risk.
- Other bisphosphonates: Do not administer OsPhos and Tildren concurrently or within close timeframes.
- Calcium supplements: High calcium intake may reduce bisphosphonate absorption (more relevant for oral formulations in other species).
Contraindications
- Horses under 4 years of age (growing bone may be adversely affected)
- Pregnant or lactating mares
- Horses with known renal disease or compromised renal function
- Severe dehydration (correct fluid status before administration)
- Known hypersensitivity to bisphosphonates
- Horses intended for food production
Storage
- OsPhos: Store at controlled room temperature. Do not freeze. Protect from light.
- Tildren: Store at room temperature. Reconstituted solution should be used promptly.
- Keep both products out of reach of children and animals.
Frequently Asked Questions
How long does it take for OsPhos or Tildren to work? Improvement is gradual. Most veterinarians evaluate response at 60 days post-treatment. Some horses show noticeable improvement in 2-4 weeks, while others take longer. The full effect of bone remodeling modulation develops over weeks to months.
How often can treatment be repeated? The general recommendation is no sooner than every 3-6 months. Your veterinarian will determine appropriate retreatment timing based on your horse’s clinical response.
Which is better, OsPhos or Tildren? Both products are effective for navicular syndrome, and head-to-head comparative studies are limited. OsPhos is simpler to administer (IM injection) and generally less expensive. Tildren requires IV infusion with monitoring. Your veterinarian will recommend the best option for your horse.
Can bisphosphonates cure navicular disease? Bisphosphonates manage the pain and slow pathologic bone remodeling, but they do not reverse existing structural damage. They are part of a multimodal approach that may include corrective farriery, controlled exercise, and other therapies.
This information is for educational purposes only and does not replace professional veterinary advice. Always consult your veterinarian before administering any medication to your horse.